Solabegron Zwitterion Crystal Forms for Scalable Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing laboratory-scale methods for producing solabegron, a β-3-adrenoceptor agonist, are not suitable for large-scale pharmaceutical production, and there is a need for alternative forms of solabegron that are effective for therapeutic uses, such as for therapeutic uses, such as for treating overactive bladder and prostate disorders, and for compositions for therapeutic purposes.
Innovation Solution
A process for preparing solabegron hydrochloride salt and solabegron zwitterion, including contacting a zwitterion with hydrochloric acid, and the discovery of two crystalline forms of solabegron zwitterion, form I and form II, which are more stable and suitable for large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If laboratory-scale methods are used to produce solabegron, then pharmaceutical quality material is obtained, but the method is not amenable to production scale
Solution Approach 1:
The patent changes the physical and chemical parameters of the solabegron compound by discovering and characterizing two distinct crystalline forms (polymorphs). Form I and Form II have different crystal structures, densities, and solubility characteristics, allowing selection of the appropriate form for large-scale production while maintaining pharmaceutical quality standards
Solution Approach 2:
The patent segments the solabegron production process by identifying and isolating specific crystalline forms through controlled crystallization conditions. This segmentation allows the process to be optimized for different stages: Form I can be used for initial crystallization while Form II is suited for final pharmaceutical formulation, enabling scalable production
2Stability of the object's composition
If alternative forms of solabegron are developed, then stability and suitability for large-scale production are improved, but process complexity increases
Solution Approach 1:
The patent utilizes phase transitions between different crystalline forms of solabegron. By controlling temperature, solvent composition, and crystallization conditions, the process can transition between Form I and Form II to achieve the desired stability profile. Form II, in particular, exhibits enhanced stability for pharmaceutical storage and handling
Solution Approach 2:
The patent employs solvent systems as intermediaries to control the crystallization process. Specific solvent combinations and ratios act as mediators that guide the formation of desired crystalline forms while simplifying the overall process by providing reproducible, controlled transformation pathways between different solabegron forms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms of solabegron zwitterion enable large-scale production and provide a stable, pure form of solabegron, allowing for its use as an active ingredient in pharmaceutical compositions for treating overactive bladder and lower urinary tract symptoms.
Implementation Method 1
contacting a zwitterion with hydrochloric acid
Implementation Method 2
the discovery of two crystalline forms of solabegron zwitterion, form I and form II
Data Source
AI summary
This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.